1,2-dimyristoyl-sn-glycero-3-phosphocholine | 18194-24-6

• 物质功能分类: 生物化工 - 脂肪类
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1,2-dimyristoyl-sn-glycero-3-phosphocholine
• 英文别名: 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine；dimyristoyl-L-α-phosphatidylcholine；L-α-dimyristoylphosphatidylcholine；L-α-dimyristoylphophatidylcholine；dimyristoyl phosphatidylcholine；DMPC；[(2S)-2,3-di(tetradecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 18194-24-6
• 化学式: C₃₆H₇₂NO₈P
• 分子量: 677.943
• InChiKey: CITHEXJVPOWHKC-UMSFTDKQSA-N

物化性质

• 熔点：
  220°C(lit.)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  11.3
• 重原子数：
  46
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• WGK Germany：
  3
• 海关编码：
  2923900090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

制备方法与用途

二肉豆蔻酰磷脂酰胆碱（DMPC）的应用

二肉豆蔻酰磷脂酰胆碱（DMPC）是一种生物化学和医药化学中的重要中间体，可用于合成多肽类药物分子、维生素以及具有特定生物活性功能的磷脂。

制备方法

1. 将干燥的反应烧瓶中加入肉豆蔻酸、甘油磷酰胆碱、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐和4-二甲氨基吡啶。
2. 依次向混合物中加入N,N-二甲基甲酰胺作为反应溶剂，然后在室温下搅拌反应数小时。通过TLC点板监测反应进度。
3. 反应结束后，将反应混合物中的有机相与水层分离，水层用乙酸乙酯萃取三次。
4. 合并所有的有机层，并用水和盐水各洗涤一次。使用无水硫酸钠干燥有机层后过滤去除干燥剂。
5. 最终，在减压真空下浓缩滤液即可得到目标产物二肉豆蔻酰磷脂酰胆碱（DMPC）。

反应信息

• 作为反应物：
  描述：

  1,2-dimyristoyl-sn-glycero-3-phosphocholine 在 phospholipase A2 、 HEPES-buffer pH 7.2 、 水 作用下， 以 氘代氯仿 为溶剂， 生成 1-myristoyl-sn-glycero-3-phosphocholine
  参考文献：
  名称：

  Phospholipase A2 catalyses in organic media

  摘要：

  Phospholipase A2 catalyses in organic solvents with low water content are described. First, the effect of the different organic media on the hydrolysis of phosphatidylcholine catalyzed by phospholipase A2 is discussed. Second, the effect of temperature on the hydrolysis of phosphatidylcholine catalyzed by phospholipase A2 in chloroform with low water content is discussed. Finally. a novel transacylation of lysophosphatidylcholine catalyzed by phospholipase A2 with long-chain acyl donors in chloroform with low water content is reported.

  DOI：

  10.1016/s0040-4039(00)91974-9
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 氯仿 、 铂 作用下， 生成 1,2-dimyristoyl-sn-glycero-3-phosphocholine
  参考文献：
  名称：

  Baer; Martin, Journal of Biological Chemistry, 1951, vol. 193, p. 835,838

  摘要：

  DOI：

文献信息

• Facile and Useful Synthesis of Enantiomeric Phosphatidylcholines.
  作者：Masami ISHIHARA、Atsunori SANO

  DOI：10.1248/cpb.44.1096

  日期：——

  The synthesis of optically active phosphatidylcholines (D- and L-4) containing two of the same fatty acid moieties in a molecule is described. Optically pure D-enantiomers (D-4) were obtained from 2, 3-di-O-acyl-sn-glycerol (D-1) in high yield by phosphorylation with phosphorus oxychloride and subsequent treatment with choline tosylate (11a). L-Enantiomers (L-4) were also prepared in a similar manner from 1, 2-di-O-acyl-sn-glycerol (L-1). The whole procedure is easy and useful for the synthesis of enantiomeric phosphatidylcholines.

  本文报道了在分子中含两个相同脂肪酸部分的具有光学活性的磷脂酰胆碱（D-4 和 L-4）的合成方法。高收率地由2,3-二-O-酰基-sn-甘油（D-1）经氯氧磷磷酸化后再与甲苯磺酸胆碱（11a）反应得到了具有光学纯的D-对映体（D-4）。L-对映体（L-4）也是以相似的方式从1,2-二-O-酰基-sn-甘油（L-1）制备得到。整个过程简便且适用于手性磷脂酰胆碱的合成。
• Method of treating disorders using a pharmaceutical composition of oligopeptides
  申请人：Goodman Simon

  公开号：US10478501B2

  公开（公告）日：2019-11-19

  The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingredients, the use of the lipophilic and/or amphiphilic compounds for making pharmaceutical compositions of said oligopeptides, and methods of making said pharmaceutical composition.

  本发明涉及一种由寡肽（最好是环状寡肽）组成的药物组合物，所述组合物进一步包含一种或多种亲脂性和/或两亲性化合物，在存在或不存在水的情况下作为主要成分；亲脂性和/或两亲性化合物用于制造所述寡肽的药物组合物；以及制造所述药物组合物的方法。
• Catheter assembly
  申请人：Chappa Ralph A.

  公开号：US10596355B2

  公开（公告）日：2020-03-24

  A catheter assembly includes an expandable and collapsible structure having an outer surface. The expandable and collapsible structure is adapted to expand between a contracted state and a dilated state. A coating is disposed on the outer surface of the expandable and collapsible structure. The coating includes a bioactive agent. A sleeve is disposed over the coating. The sleeve is adapted to expand between a compressed state and an enlarged state and to return to the compressed state. The sleeve defines a plurality of openings in the compressed state. An outer diameter of the coating is less than an outer diameter of the sleeve when the expandable and collapsible structure is in the contracted state and greater than the outer diameter of the sleeve when the expandable and collapsible structure is in the dilated state.

  导管组件包括一个具有外表面的可伸缩结构。可伸缩结构可在收缩状态和扩张状态之间伸缩。可伸缩结构的外表面上有一层涂层。涂层包括生物活性剂。涂层上有一个套筒。套筒可在压缩状态和放大状态之间膨胀并返回压缩状态。套筒在压缩状态下限定了多个开口。当可膨胀和可折叠结构处于收缩状态时，涂层的外径小于套筒的外径，而当可膨胀和可折叠结构处于扩张状态时，涂层的外径大于套筒的外径。
• Liposomal preparations for non-invasive-prenatal or cancer screening
  申请人：SeraCare Life Sciences, Inc.

  公开号：US11243212B2

  公开（公告）日：2022-02-08

  Disclosed are controls for use in identifying any of a number of genotypes and/or for use in identifying or characterizing a disease or condition. The controls may be particularly useful for diagnostic tests that utilize circulating cell-free DNA or microRNA. A control may comprise a mixture of nucleic acids. In some embodiments, a control comprises liposomes, e.g., wherein nucleic acids of the control are associated with the liposomes. For example, the controls are useful for determining whether a fetus comprises an aneuploidy. Also disclosed are methods of using the controls.

  所公开的是用于鉴定多种基因型中任何一种基因型和/或用于鉴定或描述疾病或状况的对照组。这些对照品对于利用循环无细胞 DNA 或 microRNA 的诊断测试可能特别有用。对照组可包括核酸混合物。在某些实施方案中，对照组包括脂质体，例如，对照组的核酸与脂质体相关联。例如，对照组可用于确定胎儿是否存在非整倍体。还公开了使用对照组的方法。
• Methods of enhancing immune induction involving MDA-7
  申请人：Board of Regent, The University of Texas System

  公开号：US20040009939A1

  公开（公告）日：2004-01-15

  The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.

  本发明涉及通过间接激活 PKR 来增强或诱导针对免疫原分子的免疫反应的组合物和方法。 更具体地说，通过将 MDA-7 多肽与需要针对其产生免疫反应的免疫原分子共同给药，可改善免疫疗法。 此类免疫疗法包括癌症疫苗及其组合物。